China Conditionally Approves Pamiparib for Those with Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

BeiGene has just announced that China has given conditional approval to Pamiparib, a PARP inhibitor used as a therapy for BRCA associated ovarian cancer, fallopian tube cancer, and primary peritoneal…

Continue Reading China Conditionally Approves Pamiparib for Those with Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Pamiparib for Ovarian, Fallopian, and Peritoneal Cancers Receives Conditional Approval in China
Sourced from Pixabay

Pamiparib for Ovarian, Fallopian, and Peritoneal Cancers Receives Conditional Approval in China

In China, the Conditional Approval process allows for new drugs to be marketed and developed based on an urgent and unmet need. For example, drugs which treat patients with rare…

Continue Reading Pamiparib for Ovarian, Fallopian, and Peritoneal Cancers Receives Conditional Approval in China
The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer
source: pixabay.com

The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer

Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…

Continue Reading The FDA Has Approved Niraparib (Zejula) for Platinum-Sensitive Recurrent Ovarian Cancer

Study of the Week: New Genetic Predisposition Variants in Rhabdomyosarcoma

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: New Genetic Predisposition Variants in Rhabdomyosarcoma
Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
source: pixabay.com

Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice

     The latest news from Israeli scientists, published in the Times of Israel, is that researchers at Tel Aviv University have accurately targeted cancerous cells in mice using CRISPR.…

Continue Reading Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
source: pixabay.com

New Combination for HRD-Positive Ovarian Cancer Gets EU Approval

According to a story from Cancer Network, the European Commission has recently approved a two-part combination treatment for advanced, homologous recombination deficiency (HRD)-positive ovarian cancer. This first-line maintenance treatment consists…

Continue Reading New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
A Negative Side Effect of COVID-19: Reduced Cancer Screenings
Photo by National Cancer Institute on Unsplash

A Negative Side Effect of COVID-19: Reduced Cancer Screenings

In her early 20's, Mackenzie Alleman lost her mother to breast cancer. Then, at 28, she herself underwent a preventative double mastectomy after learning that she carried the mutated BRCA1 gene.…

Continue Reading A Negative Side Effect of COVID-19: Reduced Cancer Screenings

The FDA has Extended Approval of Zejula for Ovarian Cancer Patients With and Without BRCA Mutations

GlaxoSmithKline (GSK) has just announced that Zejula, otherwise known as niraparib, has just been approved for cancer patients beyond those who have a BRCA+ mutation. The patients now included in…

Continue Reading The FDA has Extended Approval of Zejula for Ovarian Cancer Patients With and Without BRCA Mutations
Potential Treatment for BRCA Mutated Pancreatic Cancer Performs Well in Trial
mohamed_hassan / Pixabay

Potential Treatment for BRCA Mutated Pancreatic Cancer Performs Well in Trial

According to a story from BioPortfolio, AstraZeneca and Merck have recently announced the results from a phase 3 clinical trial testing olaparib (marketed as LYNPARZA®) as a treatment for BRCA…

Continue Reading Potential Treatment for BRCA Mutated Pancreatic Cancer Performs Well in Trial